PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
C Ronald Kahn Selected Research
Insulin Resistance
07/2008
Hepatic insulin resistance directly promotes formation of cholesterol gallstones.
03/2008
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance.
08/2007
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
04/2007
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
04/2006
Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia.
12/2005
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.
11/2005
Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.
07/2004
Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse.
06/2004
Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms.
08/2003
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
06/2003
Identification of interactive loci linked to insulin and leptin in mice with genetic insulin resistance.
05/2003
The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance.
Articles by Research Topic
Disease
12
Insulin Resistance
07/2008 - 05/2003
4
Syndrome
12/2007 - 07/2004
2
Obesity
11/2007 - 07/2002
1
Gallstones (Gallstone)
07/2008
1
Cardiomegaly (Heart Hypertrophy)
12/2007
1
Ischemia
04/2006
1
Hypoglycemia (Reactive Hypoglycemia)
05/2005
1
Lipodystrophy
02/2004
1
Tissue Adhesions
09/2003
1
Multiple Myeloma
09/2003
1
Retinal Neovascularization
06/2003
1
Hyperinsulinism (Hyperinsulinemia)
06/2003
1
Glucose Intolerance
07/2002
Drug/Important Bio-Agent (IBA)
7
Insulin (Novolin)
FDA Link
12/2005 - 05/2003
4
Insulin Receptor
IBA
04/2006 - 07/2002
2
Leptin
IBA
02/2004 - 06/2003
1
Cholesterol
IBA
07/2008
1
Dual-Specificity Phosphatases
IBA
03/2008
1
GTP Phosphohydrolases (GTPases)
IBA
12/2007
1
B-insulin
IBA
12/2007
1
Protons (Proton)
IBA
11/2007
1
Non-Receptor Type 1 Protein Tyrosine Phosphatase
IBA
08/2007
1
protein kinase C lambda
IBA
08/2007
1
Glucose (Dextrose)
FDA Link
Generic
08/2007
1
JNK Mitogen-Activated Protein Kinases
IBA
04/2007
1
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
IBA
04/2006
1
Liver Glycogen
IBA
12/2005
1
Glucagon-Like Peptide 1 (GLP 1)
IBA
12/2005
1
Growth Hormone (Somatotropin)
IBA
11/2005
1
Stearoyl-CoA Desaturase
IBA
05/2005
1
Suppressor of Cytokine Signaling Proteins
IBA
07/2004
1
Proteins (Proteins, Gene)
IBA
06/2004
1
Tyrosine (L-Tyrosine)
FDA Link
06/2004
1
1-Phosphatidylinositol 3-Kinase (PI 3 Kinase)
IBA
09/2003
1
PPAR gamma
IBA
08/2003
1
Thiazolidinediones
IBA
08/2003
1
IGF Type 1 Receptor (IGF 1 Receptor)
IBA
06/2003